<?xml version="1.0" encoding="UTF-8"?>
<html lang="en" dir="ltr" xmlns="http://www.w3.org/1999/xhtml">
 <head prefix="og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#"> 
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> 
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=3, minimum-scale=1, user-scalable=yes"/> 
  <meta name="type" content="article"/>
  <meta name="HW.identifier" content="/biorxiv/early/2020/04/10/2020.04.07.023903.atom"/>
  <meta name="HW.pisa" content="biorxiv;2020.04.07.023903v3"/>
  <meta name="DC.Format" content="text/html"/>
  <meta name="DC.Language" content="en"/>
  <meta name="DC.Title" content="Structural and functional analysis of a potent sarbecovirus neutralizing antibody"/>
  <meta name="DC.Identifier" content="10.1101/2020.04.07.023903"/>
  <meta name="DC.Date" content="2020-04-10"/>
  <meta name="DC.Publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="DC.Rights" content="Â© 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission."/>
  <meta name="DC.AccessRights" content="restricted"/>
  <meta name="DC.Description" content="SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than one million infections and 73,000 deaths. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of a SARS survivor infected in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease. ### Competing Interest Statement D.P., S.B., K.C., E.C., C.H-D., G.S., M.B., A.K., K.F., A.P. F.Z., S.J., B.G., A.D.M., A.L., A.T., H.W.V, R.S. and D.C. are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. M.S.D. is a consultant for Inbios, Eli Lilly, Vir Biotechnology, NGM Biopharmaceuticals, and Emergent BioSolutions and on the Scientific Advisory Board of Moderna. The Diamond laboratory at Washington University School of Medicine has received sponsored research agreements from Moderna. The other authors declare no competing financial interests."/>
  <meta name="DC.Contributor" content="Dora Pinto"/>
  <meta name="DC.Contributor" content="Young-Jun Park"/>
  <meta name="DC.Contributor" content="Martina Beltramello"/>
  <meta name="DC.Contributor" content="Alexandra C. Walls"/>
  <meta name="DC.Contributor" content="M. Alejandra Tortorici"/>
  <meta name="DC.Contributor" content="Siro Bianchi"/>
  <meta name="DC.Contributor" content="Stefano Jaconi"/>
  <meta name="DC.Contributor" content="Katja Culap"/>
  <meta name="DC.Contributor" content="Fabrizia Zatta"/>
  <meta name="DC.Contributor" content="Anna De Marco"/>
  <meta name="DC.Contributor" content="Alessia Peter"/>
  <meta name="DC.Contributor" content="Barbara Guarino"/>
  <meta name="DC.Contributor" content="Roberto Spreafico"/>
  <meta name="DC.Contributor" content="Elisabetta Cameroni"/>
  <meta name="DC.Contributor" content="James Brett Case"/>
  <meta name="DC.Contributor" content="Rita E. Chen"/>
  <meta name="DC.Contributor" content="Colin Havenar-Daughton"/>
  <meta name="DC.Contributor" content="Gyorgy Snell"/>
  <meta name="DC.Contributor" content="Amalio Telenti"/>
  <meta name="DC.Contributor" content="Herbert W. Virgin"/>
  <meta name="DC.Contributor" content="Antonio Lanzavecchia"/>
  <meta name="DC.Contributor" content="Michael S. Diamond"/>
  <meta name="DC.Contributor" content="Katja Fink"/>
  <meta name="DC.Contributor" content="David Veesler"/>
  <meta name="DC.Contributor" content="Davide Corti"/>
  <meta name="article:published_time" content="2020-04-10"/>
  <meta name="article:section" content="New Results"/>
  <meta name="citation_title" content="Structural and functional analysis of a potent sarbecovirus neutralizing antibody"/>
  <meta name="citation_abstract" lang="en" content="&lt;;p&gt;;SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than one million infections and 73,000 deaths. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of a SARS survivor infected in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease.&lt;;/p&gt;;"/>
  <meta name="citation_journal_title" content="bioRxiv"/>
  <meta name="citation_publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="citation_publication_date" content="2020/01/01"/>
  <meta name="citation_mjid" content="biorxiv;2020.04.07.023903v3"/>
  <meta name="citation_id" content="2020.04.07.023903v3"/>
  <meta name="citation_public_url" content="https://www.biorxiv.org/content/10.1101/2020.04.07.023903v3"/>
  <meta name="citation_abstract_html_url" content="https://www.biorxiv.org/content/10.1101/2020.04.07.023903v3.abstract"/>
  <meta name="citation_full_html_url" content="https://www.biorxiv.org/content/10.1101/2020.04.07.023903v3.full"/>
  <meta name="citation_pdf_url" content="https://www.biorxiv.org/content/biorxiv/early/2020/04/10/2020.04.07.023903.full.pdf"/>
  <meta name="citation_doi" content="10.1101/2020.04.07.023903"/>
  <meta name="citation_section" content="New Results"/>
  <meta name="citation_firstpage" content="2020.04.07.023903"/>
  <meta name="citation_author" content="Dora Pinto"/>
  <meta name="citation_author_institution" content="Humabs Biomed SA;"/>
  <meta name="citation_author_email" content="dpinto@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0001-5737-8467"/>
  <meta name="citation_author" content="Young-Jun Park"/>
  <meta name="citation_author_institution" content="University of Washington;"/>
  <meta name="citation_author_email" content="yjpark2@uw.edu"/>
  <meta name="citation_author" content="Martina Beltramello"/>
  <meta name="citation_author_institution" content="Humabs BioMed SA;"/>
  <meta name="citation_author_email" content="mbeltramello@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0001-5550-5629"/>
  <meta name="citation_author" content="Alexandra C. Walls"/>
  <meta name="citation_author_institution" content="University of Washington;"/>
  <meta name="citation_author_email" content="acwalls@uw.edu"/>
  <meta name="citation_author" content="M. Alejandra Tortorici"/>
  <meta name="citation_author_institution" content="University of Washington;"/>
  <meta name="citation_author_email" content="tortoric@uw.edu"/>
  <meta name="citation_author" content="Siro Bianchi"/>
  <meta name="citation_author_institution" content="Humabs Biomed SA;"/>
  <meta name="citation_author_email" content="sbianchi@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0002-5100-8905"/>
  <meta name="citation_author" content="Stefano Jaconi"/>
  <meta name="citation_author_institution" content="Humabs Biomed SA;"/>
  <meta name="citation_author_email" content="sjaconi@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0001-7527-4434"/>
  <meta name="citation_author" content="Katja Culap"/>
  <meta name="citation_author_institution" content="Humabs Biomed SA;"/>
  <meta name="citation_author_email" content="kculap@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0002-0956-0018"/>
  <meta name="citation_author" content="Fabrizia Zatta"/>
  <meta name="citation_author_institution" content="Humabs Biomed SA;"/>
  <meta name="citation_author_email" content="fzatta@vir.bio"/>
  <meta name="citation_author" content="Anna De Marco"/>
  <meta name="citation_author_institution" content="Humabs Biomed SA;"/>
  <meta name="citation_author_email" content="ademarco@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0001-9641-4838"/>
  <meta name="citation_author" content="Alessia Peter"/>
  <meta name="citation_author_institution" content="Humabs Biomed SA;"/>
  <meta name="citation_author_email" content="apeter@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0001-6636-3937"/>
  <meta name="citation_author" content="Barbara Guarino"/>
  <meta name="citation_author_institution" content="Humabs Biomed SA;"/>
  <meta name="citation_author_email" content="bguarino@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0003-3759-3252"/>
  <meta name="citation_author" content="Roberto Spreafico"/>
  <meta name="citation_author_institution" content="Vir Biotechnology;"/>
  <meta name="citation_author_email" content="rspreafico@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0001-8282-7658"/>
  <meta name="citation_author" content="Elisabetta Cameroni"/>
  <meta name="citation_author_institution" content="Humabs Biomed;"/>
  <meta name="citation_author_email" content="ecameroni@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0002-9102-8943"/>
  <meta name="citation_author" content="James Brett Case"/>
  <meta name="citation_author_institution" content="Washington University School of Medicine;"/>
  <meta name="citation_author_email" content="casejb@wustl.edu"/>
  <meta name="citation_author" content="Rita E. Chen"/>
  <meta name="citation_author_institution" content="Washington University School of Medicine;"/>
  <meta name="citation_author_email" content="ritachen@wustl.edu"/>
  <meta name="citation_author" content="Colin Havenar-Daughton"/>
  <meta name="citation_author_institution" content="Vir Biotehcnology;"/>
  <meta name="citation_author_email" content="chavenar@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0002-2880-3927"/>
  <meta name="citation_author" content="Gyorgy Snell"/>
  <meta name="citation_author_institution" content="Vir Biotechnology;"/>
  <meta name="citation_author_email" content="gsnell@vir.bio"/>
  <meta name="citation_author" content="Amalio Telenti"/>
  <meta name="citation_author_institution" content="Vir Biotechnology;"/>
  <meta name="citation_author_email" content="atelenti@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0001-6290-7677"/>
  <meta name="citation_author" content="Herbert W. Virgin"/>
  <meta name="citation_author_institution" content="Vir Biotechnology;"/>
  <meta name="citation_author_email" content="svirgin@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0001-8580-7628"/>
  <meta name="citation_author" content="Antonio Lanzavecchia"/>
  <meta name="citation_author_institution" content="Institute for Research in Biomedicine;"/>
  <meta name="citation_author_email" content="antonio.lanzavecchia@irb.usi.ch"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0002-3041-7240"/>
  <meta name="citation_author" content="Michael S. Diamond"/>
  <meta name="citation_author_institution" content="Washington University School of Medicine;"/>
  <meta name="citation_author_email" content="mdiamond@wustl.edu"/>
  <meta name="citation_author" content="Katja Fink"/>
  <meta name="citation_author_institution" content="Humabs Biomed;"/>
  <meta name="citation_author_email" content="kfink@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0002-3571-0390"/>
  <meta name="citation_author" content="David Veesler"/>
  <meta name="citation_author_institution" content="University of Washington;"/>
  <meta name="citation_author_email" content="dveesler@uw.edu"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0002-6019-8675"/>
  <meta name="citation_author" content="Davide Corti"/>
  <meta name="citation_author_institution" content="Humabs Biomed SA, subsidiary of Vir Biotechnology"/>
  <meta name="citation_author_email" content="dcorti@vir.bio"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0002-5797-1364"/>
  <meta name="twitter:title" content="Structural and functional analysis of a potent sarbecovirus neutralizing antibody"/>
  <meta name="twitter:site" content="@biorxivpreprint"/>
  <meta name="twitter:card" content="summary"/>
  <meta name="twitter:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="twitter:description" content="SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than one million infections and 73,000 deaths. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of a SARS survivor infected in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease. ### Competing Interest Statement D.P., S.B., K.C., E.C., C.H-D., G.S., M.B., A.K., K.F., A.P. F.Z., S.J., B.G., A.D.M., A.L., A.T., H.W.V, R.S. and D.C. are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. M.S.D. is a consultant for Inbios, Eli Lilly, Vir Biotechnology, NGM Biopharmaceuticals, and Emergent BioSolutions and on the Scientific Advisory Board of Moderna. The Diamond laboratory at Washington University School of Medicine has received sponsored research agreements from Moderna. The other authors declare no competing financial interests."/>
  <meta name="og-title" property="og:title" content="Structural and functional analysis of a potent sarbecovirus neutralizing antibody"/>
  <meta name="og-url" property="og:url" content="https://www.biorxiv.org/content/10.1101/2020.04.07.023903v3"/>
  <meta name="og-site-name" property="og:site_name" content="bioRxiv"/>
  <meta name="og-description" property="og:description" content="SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than one million infections and 73,000 deaths. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of a SARS survivor infected in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease. ### Competing Interest Statement D.P., S.B., K.C., E.C., C.H-D., G.S., M.B., A.K., K.F., A.P. F.Z., S.J., B.G., A.D.M., A.L., A.T., H.W.V, R.S. and D.C. are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. M.S.D. is a consultant for Inbios, Eli Lilly, Vir Biotechnology, NGM Biopharmaceuticals, and Emergent BioSolutions and on the Scientific Advisory Board of Moderna. The Diamond laboratory at Washington University School of Medicine has received sponsored research agreements from Moderna. The other authors declare no competing financial interests."/>
  <meta name="og-type" property="og:type" content="article"/>
  <meta name="og-image" property="og:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="citation_date" content="2020-04-10"/> 
  <meta name="description" content="bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution"/>
  <meta name="generator" content="Drupal 7 (http://drupal.org)"/> 
  <title>Structural and functional analysis of a potent sarbecovirus neutralizing antibody | bioRxiv</title> 
 </head>
 <body class="html not-front not-logged-in page-node page-node- page-node-1239237 node-type-highwire-article context-content hw-default-jcode-biorxiv hw-article-category-new-results"> 
  <div class="article abstract-view ">
   <span class="highwire-journal-article-marker-start"/>
   <div class="section abstract" id="abstract-1">
    <h2>Abstract</h2>
    <p id="p-2">SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than one million infections and 73,000 deaths. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of a SARS survivor infected in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease.</p>
   </div>
   <h3>Competing Interest Statement</h3>
   <p id="p-3">D.P., S.B., K.C., E.C., C.H-D., G.S., M.B., A.K., K.F., A.P. F.Z., S.J., B.G., A.D.M., A.L., A.T., H.W.V, R.S. and D.C. are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. M.S.D. is a consultant for Inbios, Eli Lilly, Vir Biotechnology, NGM Biopharmaceuticals, and Emergent BioSolutions and on the Scientific Advisory Board of Moderna. The Diamond laboratory at Washington University School of Medicine has received sponsored research agreements from Moderna. The other authors declare no competing financial interests. </p>
   <div class="section fn-group" id="fn-group-1">
    <h2>Footnotes</h2>
    <ul>
     <li class="fn-update fn-group-summary-of-updates" id="fn-1">
      <p id="p-4">After the change of the authors list I made yesterday I realized that for some reasons the supplementaries are not available. I must have done something wrong.</p>
     </li>
    </ul>
   </div>
   <span class="highwire-journal-article-marker-end"/>
  </div>
 </body>
</html>
